Alpha 2 agonists and antagonists.
The alpha 2 agonists can produce reliable dose-dependent sedation and analgesia in most species. Nevertheless, they can also produce significant physiological adverse side effects depending on dose, rate, route of administration, and the concurrent use of other CNS depressants. For this reason, it may be best to use a low dose of an alpha 2 agonist as a preanesthetic agent. The alpha 2 agonists are best suited for young, healthy, exercise-tolerant patients. The combining of low doses of alpha 2, opioid, and benzodiazepine agonists results in a synergistic CNS depressant response while minimizing the undesirable side effects of these three classes of drugs. Each group of drugs has specific antagonists available for their reversal, thus allowing veterinarians to reverse one or more of the agonists depending on the desired response. This may represent a significant advantage to the use of low-dose alpha 2 agonists in combination with opioids and benzodiazepines.
Paddleford
R R
RR
Department of Small Animal Clinical Science, University of Tennessee, College of Veterinary Medicine, Knoxville, USA. paddleford.robert@hospital.vet.utk.edu
Harvey
R C
RC
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000758:Anesthesia / Q000662:veterinary*; D019162:Anesthetics, Combined; D000818:Animals; D002415:Cats; D004285:Dogs; D006736:Horses; D007093:Imidazoles; D020926:Medetomidine; D018341:Receptors, Adrenergic, alpha-2 / Q000502:physiology; D014991:Xylazine
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D019162:Anesthetics, Combined; D007093:Imidazoles; D018341:Receptors, Adrenergic, alpha-2; D014991:Xylazine; D020926:Medetomidine